ERBB2 and breast cancer: In the randomized neoadjuvant study AVATAXHER in 142 patients with HER2+ BC, [18F]-FDG-PET/CT at baseline and after 1 cycle of docetaxel/trastuzumab was used for further treatment decisions [37].